Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Thomas

Showing results (61-70 of 155) with videos related to

Pageof 16
Sort By:
Leukemia Research|July 16, 2003
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemiaApostolia Tsimberidou, Jorge Cortes, Deborah Thomas, et al.
Cancer|April 4, 2003
Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemiaSherif Ibrahim, Iman Jilani, Susan O'Brien, et al.
Blood|October 24, 2002
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Cancer|July 2, 2003
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implicationsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
British Journal of Haematology|June 18, 2010
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemiaFabio P S Santos, Hagop Kantarjian, Carmen Fava, et al.
Leukemia Research|August 15, 2009
Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemiaJean-Marie Bruey, Hagop Kantarjian, Zeev Estrov, et al.
Leukemia Research|May 15, 2002
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemiaFarhad Ravandi, Jorge Cortes, Zeev Estrov, et al.
Cancer|December 18, 2008
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimensDushyant Verma, Susan O'Brien, Deborah Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosisSrdan Verstovsek, Ayalew Tefferi, Jorge Cortes, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2003
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemiaFrancis J Giles, Gary Guangping Shi, Jorge E Cortes, et al.
Pageof 16

Showing results (61-70 of 155) with videos related to

Sort By:
Pageof 16
Leukemia Research|July 16, 2003
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemiaApostolia Tsimberidou, Jorge Cortes, Deborah Thomas, et al.
Cancer|April 4, 2003
Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemiaSherif Ibrahim, Iman Jilani, Susan O'Brien, et al.
Blood|October 24, 2002
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Cancer|July 2, 2003
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implicationsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
British Journal of Haematology|June 18, 2010
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemiaFabio P S Santos, Hagop Kantarjian, Carmen Fava, et al.
Leukemia Research|August 15, 2009
Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemiaJean-Marie Bruey, Hagop Kantarjian, Zeev Estrov, et al.
Leukemia Research|May 15, 2002
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemiaFarhad Ravandi, Jorge Cortes, Zeev Estrov, et al.
Cancer|December 18, 2008
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimensDushyant Verma, Susan O'Brien, Deborah Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosisSrdan Verstovsek, Ayalew Tefferi, Jorge Cortes, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2003
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemiaFrancis J Giles, Gary Guangping Shi, Jorge E Cortes, et al.
Pageof 16